Keywords
Esteroides androgénicos
Tratamiento clínico
Deficiencia de andrógenos
Hipogonadismo
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To review the main scientific publications in the last 10 years (2012-2022) on the therapeutic indications of testosterone and its chemical derivatives. Bibliographic review: It is not new that Testosterone and its chemical derivatives, Anabolic Androgenic Steroids, are part of the therapeutic arsenal of modern medicine. However, its indiscriminate, abusive use and without proper medical monitoring, causes several unwanted side effects and complications, generating a great controversy around its applicability. However, there are data in the literature that support its beneficial results in the treatment of several pathological entities that course with hypogonadism, sarcopenia, and functional loss, for example. In this sense, knowledge of the correct clinical indications and adequate dosages of these androgenic hormones guarantees more therapeutic opportunities for certain deleterious conditions for the individual. Final considerations: Despite the positive evidence shown in this review, this is an area of medicine that still needs more attention and research, especially in terms of controlling unwanted side effects, the consequences of the recreational and indiscriminate use of these hormones, and also demystifying them. of its therapeutic prescription by contemporary medical professionals.
References
ABRAHIM O, et al. Prevalência do uso e conhecimento de esteroides anabolizantes androgênicos por estudantes e professores de educação física que atuam em academias de ginástica. Revista Brasileira de Medicina do Esporte, 2013; 19(1): 27-30.
ANDERSON JL, et al. Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. Am J Cardiol, 2016; 117(5): 794–9.
BEBO JUNIOR BF, et al. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol, 1999; 162: 35–40.
BEVILACQUA G, et al. Percepções sobre risco e efeitos do uso e consumo de esteroides anabolizantes por praticantes de musculação. Caderno Educação física e Esporte: Paraná, 2016; 14(2): 07.
BEZERRA A, et al. Riscos relacionados ao uso de anabolizantes esteróides para fins estéticos. Research, Society and Development, 2022; 11(7): e18811729983.
BOJESEN A, et al. Klinefelter syndrome, type 2 diabetes and metabolic syndrome: the impact of body composition. Mol Hum Reprod, 2010; 16: 396–401.
BREX PA, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. New England Journal of Medicine, 2002; 158-164.
CHAPMAN IM, et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr, 2009; 89: 880-9.
CHEETHAM TC, et al. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency. JAMA Intern Med, 2017; 177(4): 491–9.
CHITNIS T. The role of testosterone in MS risk and course. Multiple Sclerosis Journal, 2018; 24(1): 36-4.
DIAZ EC, et al. Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burns. Burns, 2015; 41(4): 649-657.
FINKLE WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 2014; 9(1): e85805.
FREEMAN ER, et al. A brief history of testosterone. The Journal Of Urology, 2001; 165: 371- 373. 14.
GARCÍA-CRUZ E, ALCARAZ A. Testosterone deficiency syndrome: Diagnosis and treatment. Actas Urol Esp (Engl Ed), 2020; 44(5): 294-300.
GLENN R, et al. Association of Sex Hormones With Sexual Function, Vitality, and Physical Function of Symptomatic Older Men With Low Testosterone Levels at Baseline in the Testosterone Trials. The Journal of Clinical Endocrinology & Metabolism, 2015; Pages 1146–1155G.
GUS EI, et al. Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned. Burns, 2020, 46(1): 19-32.
HERNDON D, et al. Reversal of Growth Arrest with the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children. Annals of surgery, 2016; 264(3): 421–428.
HOST C, et al. The role of hypogonadism in Klinefelter Syndrome. Asian J Androl., 2014; 16: 185-91. MORLEY JE. Sarcopenia in the Elder, Family Practice, 2012; 29(suppl_1): i44–i48.
HOBERMAN JM. Testosterone Dreams: Rejuvenation, aphrodisia, doping. University of California Press, 2005.
KLAUDE M, et al. Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis. Clin Sci (Lond), 2012; 122(3): 133–42.
KRUMHOLZ HM. Post-hospital syndrome–an acquired, transient condition of generalized risk. N Engl J Med., 2013; 368: 100–102.
MORGUNOV LY, et al. Hypogonadism and its treatment after ischemic stroke in men with type 2 diabetes mellitus. The Aging Male, 2020, 23(1): 71-80.
MAVROS Y, et al. Oxandrolone enhances resistance training in older women. Medicine and Science in Sport and Exercise, 2015; 47(1): 2257-2267.
DAVIS MP, PANIKKAR P. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Annals of Palliative Medicine, 2019; 8(1).
MORLEY JE. Weight loss in older persons: new therapeutic approaches. Curr Pharm Des, 2007, 13: 3637-47.
NIGHTINGALE TE, et al. Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review. J Spinal Cord Med, 2018; 41(6): 624-636.
DEER RR, et al. A Randomized Controlled Pilot Trial of Interventions to Improve Functional Recovery After Hospitalization in Older Adults: Feasibility and Adherence. The Journals of Gerontology: Series A, 2018; 2: 187–193.
ROJAS Y, et al. Burns: an update on current pharmacotherapy. Expert Opin Pharmacother, 2012, 13(17): 2485-94.
SAAD F, et al. Testosterone Deficiency and Testosterone Treatment in Older Men. Gerontology, 2017, 63: 144-156.
SRINIVAS-SHANKAR U, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab, 2010; 95(2): 639–50.
TAUCHEN J, et al. Medicinal Use of Testosterone and Related Steroids Revisited. Molecules, 2021; 26(4): 1032.
THOMAS W, et al. Effects of Testosterone Supplementation for 3 Years on Muscle Performance and Physical Function in Older Men. The Journal of Clinical Endocrinology & Metabolism, 2017; 583–593.
VIGEVENO RM, et al. Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. Journal of Magnetic Resonance Imaging: JMRI, 2012; 1-19.
WOSNITZER MS, PADUCH DA. Endocrinological issues and hormonal manipulation in children and men with Klinefelter syndrome. Am J Med Genet Part C Semin Med Genet, 2013; 163C: 16–26.
WRIGHT TJ, et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J Cachexia Sarcopenia Muscle, 2018; 9(3): 482-496.
YABLUCHANSKIY A, et al. Is Testosterone Replacement Therapy in Older Men Effective and Safe? Drugs Aging, 2019; 36(11): 981-989.